Ulrike Baum Selected Research

aziridine-2,3-dicarboxylate

12/2010

Aziridine-2,3-dicarboxylate-based cysteine cathepsin inhibitors induce cell death in Leishmania major associated with accumulation of debris in autophagy-related lysosome-like vacuoles.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ulrike Baum Research Topics

Disease

7	Human Influenza (Influenza) 01/2022 - 09/2015
3	Infections 01/2022 - 12/2010
2	COVID-19 01/2022 - 01/2021
2	Chronic Disease (Chronic Diseases) 01/2021 - 01/2021
1	Asthma (Bronchial Asthma) 01/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Measles 07/2020
1	Mumps 07/2020
1	Rubella (German Measles) 07/2020
1	Consciousness Disorders 01/2018
1	Rupture 12/2010

Drug/Important Bio-Agent (IBA)

7	VaccinesIBA 01/2022 - 09/2016
4	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022 - 09/2015
1	ORALIT (ORS)IBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA 07/2020
1	PeptidomimeticsIBA 12/2010
1	aziridine-2,3-dicarboxylateIBA 12/2010
1	EnzymesIBA 12/2010

Therapy/Procedure

1	Electrodes (Electrode) 01/2018